Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

7500 Background: Increased selectivity of the Bruton tyrosine kinase inhibitor (BTKi) acalabrutinib (Aca) vs ibrutinib (Ib) may improve tolerability. We conducted an open-label, randomized, noninferiority, phase 3 trial to compare Aca vs Ib in patients (pts) with chronic lymphocytic leukemia (CLL). Methods: Previously treated CLL pts with del(17p) or del(11q) by central lab were randomized to...

  • 123456 Profile photo of Madelyn

    Long awaiting head to head data of BTK in CLL. Aca was noninferior to Ibr with a median PFS of 38.4 mo in both arms. Although acala had less afib then ibr (9.4% vs 16.0%), afib was still prevalent. Overall, better tolerated but requires BID administration.